Effects of Abatacept in Patients With Early Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-jRCT2080223027
- Lead Sponsor
- Bristol-Myers Squibb K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Rheumatoid arthritis (RA) diagnosis less than 6 months
CRP greater than 3 mg/L or Erythrocyte Sedimentation Rate (ESR) not less than 28 mm/h
At least 3 swollen and 3 tender joints
Anti-citrullinated protein antibodies (ACPA) positive
Exclusion Criteria
At risk for tuberculosis
Have acute infection
Have chronic or recurrent bacterial or serious latent viral infection
History of malignancies in the last 5 years except squamous skin, basal skin or cervical carcinoma
Previous treatment with any conventional or biologic Disease-modifying anti rheumatic drugs (DMARD)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method